

## PRESS RELEASE

**innate** pharma

---

### **INNATE PHARMA ANNOUNCES ITS FINANCIAL AND INVESTOR RELATIONS CALENDAR FOR 2009**

**Marseilles, December 23, 2008**


---

Innate Pharma (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, announces its tentative financial and investor relations calendar for 2009.

The tentative financial calendar was set as follows:

- |                    |   |
|--------------------|---|
| February 6, 2009:  | Publication of revenue for 4Q2008 and for fiscal year 2008, with management comments  |
| February 27, 2009: | Publication of 2008 financial statements, with management comments<br>The 2008 Reference Document and Financial Report (included in the Reference Document) will be released at the end of March. |
| May 5, 2009:       | Publication of revenue for 1Q2009, with management comments   |
| June 23, 2009:     | Annual shareholders meeting, in Marseilles  |
| August 31, 2009:   | Publication of mid-year financial statements as of June 30, 2009, with management comments  |
| November 6, 2009:  | Publication of revenue for 3Q2009, with management comments   |
| February 5, 2010:  | Publication of revenue for 4Q2009 and for fiscal year 2009, with management comments  |

All corporate information on the company such as its financial statements or its corporate presentations is available on the company's website ([www.innate-pharma.com](http://www.innate-pharma.com)), in the investor documentation centre, Investors' section.



## PRESS RELEASE

**innate** pharma

---

### About Innate Pharma

Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006, Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class\* drugs targeting innate immunity.

The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings.

Besides oncology, Innate Pharma's drug candidates have development potential in the treatment of infectious disease and chronic inflammation. Two of the Company's molecules are undergoing clinical development, the most advanced being today in Phase II trials in cancer and infections.

With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing immunotherapeutics market.

Based in Marseilles, France, Innate Pharma had 88 employees as of September 30, 2008.

### Practical Information

**ISIN code** FR0010331421  
**Ticker code** IPH

### Disclaimer

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

### For any additional information, please contact

#### **Innate Pharma**

Laure-Hélène Mercier,  
Director, Investor Relations  
Phone: +33 (0)4 88 66 05 87  
lmercier@innate-pharma.fr

#### **Alize Public Relations**

Caroline Carmagnol  
Phone: +33 (0)1 41 22 07 31  
Mob: +33 (0)6 64 18 99 59  
caroline@alizerp.com

---

\* with new mechanisms of action.